Maravai LifeSciences(MRVI) Prnewswire·2025-03-04 00:59Core Viewpoint - Maravai LifeSciences Holdings, Inc is under investigation for potential securities fraud and unlawful business practices following a delay in its earnings release for Q4 and full year 2024, which led to a significant drop in its stock price [1][2]. Group 1: Company Overview - Maravai LifeSciences Holdings, Inc is publicly traded on NASDAQ under the ticker MRVI [1]. - The company announced a delay in its fourth quarter and full year 2024 earnings release on February 25, 2025, citing the need for additional time to complete its year-end financial close process [2]. Group 2: Stock Performance - Following the announcement of the earnings delay, Maravai's stock price fell by 3.14 per share on February 25, 2025 [2]. Group 3: Legal Context - Pomerantz LLP is investigating claims on behalf of investors regarding potential securities fraud or other unlawful business practices by Maravai and its officers and/or directors [1]. - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for the rights of victims of securities fraud [3].